CU20210016A7 - Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 - Google Patents
Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6Info
- Publication number
- CU20210016A7 CU20210016A7 CU2021000016A CU20210016A CU20210016A7 CU 20210016 A7 CU20210016 A7 CU 20210016A7 CU 2021000016 A CU2021000016 A CU 2021000016A CU 20210016 A CU20210016 A CU 20210016A CU 20210016 A7 CU20210016 A7 CU 20210016A7
- Authority
- CU
- Cuba
- Prior art keywords
- hydroxy
- substituted
- dioxocyclobutenylamine
- picolinamides
- ccr6
- Prior art date
Links
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 title 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- -1 N-substituted dioxocyclobutenylamino-3-hydroxy-picolinamide compounds Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Abstract
<p>La presente invención se refiere a compuestos de dioxociclobutenilamino-3-hidroxi-picolinamida N-sustituida de las fórmulas (IA y IB)</p> <p>ESPACIO PARA FÓRMULAS</p> <p>,o una sal o hidrato de aquellos aceptables desde el punto de vista farmacéutico, donde las variables R1, R2, R3, A y B se definen en la presente; a composiciones farmacéuticas que contienen estos compuestos.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862734486P | 2018-09-21 | 2018-09-21 | |
PCT/IB2019/057856 WO2020058869A1 (en) | 2018-09-21 | 2019-09-18 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20210016A7 true CU20210016A7 (es) | 2021-10-12 |
Family
ID=68051869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2021000016A CU20210016A7 (es) | 2018-09-21 | 2019-09-18 | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 |
Country Status (29)
Country | Link |
---|---|
US (2) | US10975065B2 (es) |
EP (1) | EP3852879A1 (es) |
JP (1) | JP6989729B2 (es) |
KR (2) | KR102615234B1 (es) |
CN (2) | CN116874466A (es) |
AR (1) | AR116464A1 (es) |
AU (1) | AU2019344107B2 (es) |
BR (1) | BR112021003956A2 (es) |
CA (1) | CA3055805A1 (es) |
CL (1) | CL2021000683A1 (es) |
CO (1) | CO2021003391A2 (es) |
CR (1) | CR20210146A (es) |
CU (1) | CU20210016A7 (es) |
DO (1) | DOP2021000045A (es) |
EA (1) | EA202190586A1 (es) |
EC (1) | ECSP21018584A (es) |
GE (1) | GEP20237476B (es) |
IL (1) | IL281634A (es) |
MA (1) | MA53643A (es) |
MX (1) | MX2021003318A (es) |
NI (1) | NI202100012A (es) |
NZ (1) | NZ773473A (es) |
PE (1) | PE20211070A1 (es) |
PH (1) | PH12021550554A1 (es) |
SG (1) | SG11202101827RA (es) |
TW (1) | TWI754172B (es) |
UY (1) | UY38379A (es) |
WO (1) | WO2020058869A1 (es) |
ZA (1) | ZA202101169B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA202190586A1 (ru) * | 2018-09-21 | 2021-07-05 | Пфайзер Инк. | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6 |
KR20230005938A (ko) | 2020-04-30 | 2023-01-10 | 이도르시아 파마슈티컬스 리미티드 | Ccr6 수용체 조절인자로서의 아제티딘-3-일메탄올 유도체 |
WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
TW202325278A (zh) | 2021-10-26 | 2023-07-01 | 瑞士商愛杜西亞製藥有限公司 | Ccr6受體調節劑 |
WO2023073082A1 (en) | 2021-10-28 | 2023-05-04 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354763A (en) | 1993-11-17 | 1994-10-11 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
US5466712A (en) | 1994-11-04 | 1995-11-14 | American Home Products Corporation | Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones |
DK0796243T3 (da) | 1994-11-16 | 1999-09-13 | American Home Prod | Diaminocyclobuten-3,4-dioner |
DK0901786T3 (da) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
US6495576B2 (en) | 2001-02-07 | 2002-12-17 | Abbott Laboratories | Aminal diones as potassium channel openers |
PL207255B1 (pl) | 2001-04-16 | 2010-11-30 | Pharmacopeia Drug Discovery | 3,4-di-podstawione cyklobuten-1,2-diony i ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna |
CA2479126C (en) | 2002-03-18 | 2011-11-15 | Schering Corporation | Combination treatments for chemokine-mediated diseases |
ATE422203T1 (de) * | 2002-10-09 | 2009-02-15 | Schering Corp | Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden |
CA2598460C (en) | 2005-02-16 | 2013-05-07 | Schering Corporation | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
CA2648033A1 (en) | 2006-03-31 | 2007-10-11 | Janssen Pharmaceutica N.V. | 3,4-diamino-3-cyclobutene-1,2-dione derivatives as potassium channel openers |
WO2007140233A1 (en) | 2006-05-26 | 2007-12-06 | Abbott Laboratories | Inhibitors of polo-like kinases |
MX2009000123A (es) | 2006-07-07 | 2009-03-25 | Schering Corp | Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos del receptor de quimiocina-cxc. |
MX2009011754A (es) | 2007-04-30 | 2009-12-01 | Abbott Lab | Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1. |
WO2009015164A2 (en) | 2007-07-24 | 2009-01-29 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
CN101772485A (zh) | 2007-06-06 | 2010-07-07 | 诺瓦提斯公司 | 抗炎的被取代的环丁烯二酮化合物 |
JP2010532357A (ja) | 2007-07-05 | 2010-10-07 | シェーリング コーポレイション | 1,2−置換3,4−ジオキソ−1−シクロブテン化合物における制御された結晶サイズのための方法 |
WO2009012375A2 (en) | 2007-07-19 | 2009-01-22 | Wyeth | Squarate kinase inhibitors |
JP5292400B2 (ja) | 2007-07-24 | 2013-09-18 | ブリストル−マイヤーズ スクイブ カンパニー | ケモカイン受容体活性のモジュレーターとしてのピペリジン誘導体 |
CA2706883A1 (en) | 2007-12-04 | 2009-06-11 | Schering Corporation | Methods of treating copd |
UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
WO2010131146A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
JP5699149B2 (ja) | 2009-09-04 | 2015-04-08 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Bruton型チロシンキナーゼ阻害薬 |
CN102711766B (zh) | 2009-11-12 | 2014-06-04 | 霍夫曼-拉罗奇有限公司 | N-9-取代的嘌呤化合物、组合物和使用方法 |
FR2961695B1 (fr) | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
US8648070B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments |
US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
MX2014002459A (es) | 2011-08-30 | 2014-04-10 | Chdi Foundation Inc | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. |
FR2981935B1 (fr) | 2011-10-28 | 2015-08-07 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
FR2981934B1 (fr) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
FR2981936B1 (fr) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
EP2852439A1 (en) | 2012-05-23 | 2015-04-01 | Stemergie Biotechnology SA | Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof |
WO2014097151A2 (en) | 2012-12-19 | 2014-06-26 | Novartis Ag | Autotaxin inhibitors |
CN104936949A (zh) | 2013-01-25 | 2015-09-23 | 百时美施贵宝公司 | 用于治疗丙型肝炎的squaric衍生物 |
US10138256B2 (en) | 2013-03-15 | 2018-11-27 | Celgene Car Llc | MK2 inhibitors and uses thereof |
FR3030515B1 (fr) | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Cxcr2抑制劑 |
TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
US10660909B2 (en) * | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
EA202190586A1 (ru) * | 2018-09-21 | 2021-07-05 | Пфайзер Инк. | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6 |
-
2019
- 2019-09-18 EA EA202190586A patent/EA202190586A1/ru unknown
- 2019-09-18 WO PCT/IB2019/057856 patent/WO2020058869A1/en active Application Filing
- 2019-09-18 CA CA3055805A patent/CA3055805A1/en active Pending
- 2019-09-18 PE PE2021000331A patent/PE20211070A1/es unknown
- 2019-09-18 AU AU2019344107A patent/AU2019344107B2/en active Active
- 2019-09-18 MX MX2021003318A patent/MX2021003318A/es unknown
- 2019-09-18 BR BR112021003956-2A patent/BR112021003956A2/pt unknown
- 2019-09-18 CN CN202310857008.9A patent/CN116874466A/zh active Pending
- 2019-09-18 KR KR1020217007932A patent/KR102615234B1/ko active IP Right Grant
- 2019-09-18 EP EP19773556.6A patent/EP3852879A1/en active Pending
- 2019-09-18 GE GEAP201915588A patent/GEP20237476B/en unknown
- 2019-09-18 JP JP2021514571A patent/JP6989729B2/ja active Active
- 2019-09-18 MA MA053643A patent/MA53643A/fr unknown
- 2019-09-18 CN CN201980058547.8A patent/CN112672791B/zh active Active
- 2019-09-18 CU CU2021000016A patent/CU20210016A7/es unknown
- 2019-09-18 SG SG11202101827RA patent/SG11202101827RA/en unknown
- 2019-09-18 NZ NZ773473A patent/NZ773473A/en unknown
- 2019-09-18 CR CR20210146A patent/CR20210146A/es unknown
- 2019-09-18 KR KR1020237043152A patent/KR20230175326A/ko active Application Filing
- 2019-09-19 UY UY0001038379A patent/UY38379A/es unknown
- 2019-09-20 AR ARP190102673A patent/AR116464A1/es unknown
- 2019-09-20 TW TW108134010A patent/TWI754172B/zh active
- 2019-09-20 US US16/576,997 patent/US10975065B2/en active Active
-
2021
- 2021-02-22 ZA ZA2021/01169A patent/ZA202101169B/en unknown
- 2021-02-24 NI NI202100012A patent/NI202100012A/es unknown
- 2021-03-05 US US17/192,968 patent/US11708360B2/en active Active
- 2021-03-12 PH PH12021550554A patent/PH12021550554A1/en unknown
- 2021-03-16 CO CONC2021/0003391A patent/CO2021003391A2/es unknown
- 2021-03-16 EC ECSENADI202118584A patent/ECSP21018584A/es unknown
- 2021-03-18 IL IL281634A patent/IL281634A/en unknown
- 2021-03-19 DO DO2021000045A patent/DOP2021000045A/es unknown
- 2021-03-19 CL CL2021000683A patent/CL2021000683A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20210016A7 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
CO2022008091A2 (es) | Inhibidores de kras g12c | |
CU20200080A7 (es) | Kit que comprende un inhibidor de lats para el suministro ocular | |
CL2019003086A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
CL2018001145A1 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
CL2020000610A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos. | |
UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
CU24496B1 (es) | Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk | |
CU20160052A7 (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
CR20140413A (es) | Inhibidores de serina/treonina cinasa | |
CL2018000007A1 (es) | Compuestos inhibidores de la señalización de la vía de notch | |
DOP2021000088A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
CL2019003669A1 (es) | Inhibidores de quinasa alk2 que contienen imidazol. | |
CL2021001461A1 (es) | Moduladores de trex1 | |
EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
CR20190236A (es) | Compuestos terapéuticos y métodos para utilizarlos | |
UY37941A (es) | Derivados de bencimidazol y sus usos | |
UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
CL2017002354A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. | |
CO2018004572A2 (es) | Inhibidores de calicreína plasmática humana | |
UY38892A (es) | Moduladores de sting (estimulador de genes de interferón) | |
ECSP20066271A (es) | Derivados de pirazo-tetrahidroisoquinolina como moduladores positivos del receptor de dopamina d1 | |
CO2021004873A2 (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
CU20190028A7 (es) | Compuestos de indazol útiles en lesiones de tendones y/o ligamentos | |
EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека |